08241662 cites 225 patents.

The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder. In some aspects, the composition may be presented in the form of an unoccluded or free form topically administered gel.

Title
Unoccluded topical oxybutynin gel composition and methods for transdermal oxybutynin therapy
Application Number
11/645076
Publication Number
8241662 (B2)
Application Date
December 21, 2006
Publication Date
August 14, 2012
Inventor
Steven W Sanders
Salt Lake City
UT, US
Charles D Ebert
Salt Lake City
UT, US
Agent
Florek & Endres PLLC
Assignee
Watson Laboratories
UT, US
IPC
A61K 9/70
A61L 15/16
A61F 13/02
A61F 13/00
View Original Source